Relevant bibliographies by topics / Targetted liposome

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Targetted liposome'

Author: Grafiati
Published: 4 June 2021
Last updated: 3 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Targetted liposome.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Targetted liposome"

1

Sivathanu, Dr S. Bhagavathy, Shivapriya G, and Shivapriya G. "Formulation, Characterization and In vitro Drug Delivery of Vitexin Loaded Liposomes." International Journal of Pharmaceutical Sciences and Nanotechnology 14, no. 2 (April 30, 2021): 5364–71. http://dx.doi.org/10.37285/ijpsn.2021.14.2.2.

Full text
Abstract:
Liposome is a spherical vesicle which contains atleast one lipid bilayer. Liposomes are used as a novel drug carriers because of its hydrophobic and hydrophilic nature, it has many advantages in the field of medical sciences. There are some other drug carriers like dendrimers, micelles, niosomes. Out of all, liposomes are considered to be the most promising agent for drug delivery. The uniqueness of liposome is when it is used as a pharmaceutical drug, it acts as a natural receptor. Thus it acts as an antigen and binds with the antibody (cancer cell) without causing any damage to the adjacent cells. For the synthesis of liposomes, a phospholipid is required. The liposomes can be synthesized using egg yolk and chloroform. So the basic phospholipid is obtained from egg yolk. For more stability, the liposomes are prepared using popc. The present work discuss about the effective preparation of drug loaded liposomes using popc (1- palmitoyl-2-oleoyl-sn-glycero-3- phosphocholine). POPC is an important phospholipid for biophysical experiments. Additionally chloroform is used as the solvent for the liposome preparation. The drug chosen for liposome loading is vitexin (vxn), which is an effective therapeutic agent against inflammation and cancer. The vesicular size, shape, drug entrapment efficacy, stability, electrochemical property and drug releasing property of the formulated liposomes were characterized. The results showed that the formulated liposomes are considered as the better drug carrier system and good choice for biotransformation within the cell to reach the target site such as cancer cells. Even though available treatments like chemotherapy and radiation therapy, causes damage to the surrounding cells, the alternative drug transferring system such as liposomal mediated drug transfer within the cell is considered as good choice of treatment to avoid such complications. The aim of liposome mediated drug carrier system is to develop a method to reach the drug to the target site. After drug delivery at the target site, the liposomes are fused within the surface of the body. This is because of the pH of liposomes, which is at 7.4 and temperature is maintained at 37 oC. So, the vxn loaded liposomes are considered as the novel drug carriers for the successful targetted drug delivery.
APA, Harvard, Vancouver, ISO, and other styles
2

Cattel, Luigi, Maurizio Ceruti, and Franco Dosio. "From Conventional to Stealth Liposomes a new Frontier in Cancer Chemotherapy." Tumori Journal 89, no. 3 (May 2003): 237–49. http://dx.doi.org/10.1177/030089160308900302.

Full text
Abstract:
Many attempts have been made to achieve good selectivity to targeted tumor cells by preparing specialized carrier agents that are therapeutically profitable for anticancer therapy. Among these, liposomes are the most studied colloidal particles thus far applied in medicine and in particular in antitumor therapy. Although they were first described in the 1960s, only at the beginning of 1990s did the first therapeutic liposomes appear on the market. The first-generation liposomes (conventional liposomes) comprised a liposome-containing amphotericin B, Ambisome (Nexstar, Boulder, CO, USA), used as an antifungal drug, and Myocet (Elan Pharma Int, Princeton, NJ, USA), a doxorubicin-containing liposome, used in clinical trials to treat metastatic breast cancer. The second-generation liposomes (“pure lipid approach”) were long-circulating liposomes, such as Daunoxome, a daunorubicin-containing liposome approved in the US and Europe to treat AIDS-related Kaposi's sarcoma. The third-generation liposomes were surface-modified liposomes with gangliosides or sialic acid, which can evade the immune system responsible for removing liposomes from circulation. The fourth-generation liposomes, pegylated liposomal doxorubicin, were called “stealth liposomes” because of their ability to evade interception by the immune system, in the same way as the stealth bomber was able to evade radar. Actually, the only stealth liposome on the market is Caelyx/Doxil (Schering-Plough, Madison NJ, USA), used to cure AIDS-related Kaposi's sarcoma, resistant ovarian cancer and metastatic breast cancer. Pegylated liposomal doxorubicin is characterized by a very long-circulation half-life, favorable pharmacokinetic behavior and specific accumulation in tumor tissues. These features account for the much lower toxicity shown by Caelyx in comparison to free doxorubicin, in terms of cardiotoxicity, vesicant effects, nausea, vomiting and alopecia. Pegylated liposomal doxorubicin also appeared to be less myelotoxic than doxorubicin. Typical forms of toxicity associated to it are acute infusion reaction, mucositis and palmar plantar erythrodysesthesia, which occur especially at high doses or short dosing intervals. Active and cell targeted liposomes can be obtained by attaching some antigen-directed monoclonal antibodies (Moab or Moab fragments) or small proteins and molecules (folate, epidermal growth factor, transferrin) to the distal end of polyethylene glycol in pegylated liposomal doxorubicin. The most promising therapeutic application of liposomes is as non-viral vector agents in gene therapy, characterized by the use of cationic phospholipids complexed with the negatively charged DNA plasmid. The use of liposome formulations in local-regional anticancer therapy is also discussed. Finally, pegylated liposomal doxorubicin containing radionuclides are used in clinical trials as tumor-imaging agents or in positron emission tomography.
APA, Harvard, Vancouver, ISO, and other styles
3

Gorbik, V. S., Z. S. Shprakh, Z. M. Kozlova, and V. G. Salova. "LIPOSOMES AS A TARGETED DELIVERY SYSTEM OF DRUGS (REVIEW)." Russian Journal of Biotherapy 20, no. 1 (April 8, 2021): 33–41. http://dx.doi.org/10.17650/1726-9784-2021-20-1-33-41.

Full text
Abstract:
Liposomal targeted drug delivery makes it possible to achieve effective concentration in the target cell under various pathological conditions. The main advantage of liposomal particles is their biodegradability and immunological neutrality, which improves the safety profile of drugs. The review provides information on the composition of liposomes: the main component of the liposomal membrane is phospholipids, which provide its strength and protect from mechanical impacts. Liposomal particles are distinguished by the size and number of bilayer membranes, also secreted liposomes with a non‑lamellar organization. The composition and size of liposomes are selected depending on the purpose, including excipients in the membrane that affect the properties and functions of liposomes, including the rate of release of the components, the affinity of liposomes for the target tissue, etc. The review considers the main methods for obtaining liposomes and the features of their use, advantages and disadvantages. The creation of liposomes that are sensitive to various external or internal physicochemical factors makes it possible to realize drugs effects, localize the site of its action and reduce the number and severity of side effects. Currently, liposome‑based drugs are successfully used in various fields of medicine – dermatology, cardiology, oncology, neurology, etc. The most active condact preclinical and clinical studies of liposomal drugs for the treatment of malignant neoplasms. Particular attention is paid to the work of Russian researchers in the field of targeted drug delivery. It is shown that today liposomes are an open for study and improvement system for targeted drug delivery.
APA, Harvard, Vancouver, ISO, and other styles
4

Medina, Oula Peñate, Tuula Peñate Medina, Jana Humbert, Bao Qi, Wolfgang Baum, Olga Will, Timo Damm, and Claus Glüer. "Using Alendronic Acid Coupled Fluorescently Labelled SM Liposomes as a Vehicle for Bone Targeting." Current Pharmaceutical Design 26, no. 46 (December 30, 2020): 6021–27. http://dx.doi.org/10.2174/1381612826666200614175905.

Full text
Abstract:
Background: We recently developed a liposomal nanoparticle system that can be used for drug delivery and simultaneously be monitored by optical or photoacoustic imaging devices. Here we tested the efficacy of alendronate as a homing molecule in SM-liposomes for bone targeting. Methods: Alendronate was immobilized covalently on the liposomal surface and the fluorescent dye indocyanine green was used as a payload in the liposomes. The indocyanine green delivery was analyzed by 3D optical tomography, optical fluorescence scanner, photoacoustic imaging, and by ex-vivo biodistribution studies. Results: The results show that the alendronate, coupled to the liposomal surface, increases sphingomyelin containing liposome targeting up to several-folds. Conclusion: The alendronate targeted liposomes open possibilities for an application in active bone targeting.
APA, Harvard, Vancouver, ISO, and other styles
5

Tansi, Felista L., Ronny Rüger, Ansgar M. Kollmeier, Markus Rabenhold, Frank Steiniger, Roland E. Kontermann, Ulf K. Teichgräber, Alfred Fahr, and Ingrid Hilger. "Targeting the Tumor Microenvironment with Fluorescence-Activatable Bispecific Endoglin/Fibroblast Activation Protein Targeting Liposomes." Pharmaceutics 12, no. 4 (April 17, 2020): 370. http://dx.doi.org/10.3390/pharmaceutics12040370.

Full text
Abstract:
Liposomes are biocompatible nanocarriers with promising features for targeted delivery of contrast agents and drugs into the tumor microenvironment, for imaging and therapy purposes. Liposome-based simultaneous targeting of tumor associated fibroblast and the vasculature is promising, but the heterogeneity of tumors entails a thorough validation of suitable markers for targeted delivery. Thus, we elucidated the potential of bispecific liposomes targeting the fibroblast activation protein (FAP) on tumor stromal fibroblasts, together with endoglin which is overexpressed on tumor neovascular cells and some neoplastic cells. Fluorescence-quenched liposomes were prepared by hydrating a lipid film with a high concentration of the self-quenching near-infrared fluorescent dye, DY-676-COOH, to enable fluorescence detection exclusively upon liposomal degradation and subsequent activation. A non-quenched green fluorescent phospholipid was embedded in the liposomal surface to fluorescence-track intact liposomes. FAP- and murine endoglin-specific single chain antibody fragments were coupled to the liposomal surface, and the liposomal potentials validated in tumor cells and mice models. The bispecific liposomes revealed strong fluorescence quenching, activatability, and selectivity for target cells and delivered the encapsulated dye selectively into tumor vessels and tumor associated fibroblasts in xenografted mice models and enabled their fluorescence imaging. Furthermore, detection of swollen lymph nodes during intra-operative simulations was possible. Thus, the bispecific liposomes have potentials for targeted delivery into the tumor microenvironment and for image-guided surgery.
APA, Harvard, Vancouver, ISO, and other styles
6

Peñate-Medina, Tuula, Christabel Damoah, Miriam Benezra, Olga Will, Kalevi Kairemo, Jana Humbert, Susanne Sebens, and Oula Peñate-Medina. "Alpha-MSH Targeted Liposomal Nanoparticle for Imaging in Inflammatory Bowel Disease (IBD)." Current Pharmaceutical Design 26, no. 31 (September 17, 2020): 3840–46. http://dx.doi.org/10.2174/1381612826666200727002716.

Full text
Abstract:
Background: The purpose of our study was to find a novel targeted imaging and drug delivery vehicle for inflammatory bowel disease (IBD). IBD is a common and troublesome disease that still lacks effective therapy and imaging options. As an attempt to improve the disease treatment, we tested αMSH for the targeting of nanoliposomes to IBD sites. αMSH, an endogenous tridecapeptide, binds to the melanocortin-1 receptor (MC1-R) and has anti-inflammatory and immunomodulating effects. MC1-R is found on macrophages, neutrophils and the renal tubule system. We formulated and tested a liposomal nanoparticle involving αMSH in order to achieve a specific targeting to the inflamed intestines. Methods: NDP-αMSH peptide conjugated to Alexa Fluor™ 680 was linked to the liposomal membrane via NSuccinyl PE and additionally loaded into the lumen of the liposomes. Liposomes without the αMSH-conjugate and free NDP-αMSH were used as a control. The liposomes were also loaded with ICG to track them. The liposomes were tested in DSS treated mice, which had received DSS via drinking water order to develop a model IBD. Inflammation severity was assessed by the Disease Activity Index (DAI) score and ex vivo histological CD68 staining of samples taken from different parts of the intestine. The liposome targeting was analyzed by analyzing the ICG and ALEXA 680 fluorescence in the intestine compared to the biodistribution. Results: NPD-αMSH was successfully labeled with Alexa and retained its biological activity. Liposomes were identified in expected regions in the inflamed bowel regions and in the kidneys, where MC1-R is abundant. In vivo liposome targeting correlated with the macrophage concentration at the site of the inflammation supporting the active targeting of the liposomes through αMSH. The liposomal αMSH was well tolerated by animals. Conclusions: This study opens up the possibility to further develop an αMSH targeted theranostic delivery to different clinically relevant applications in IBD inflammation but also opens possibilities for use in other inflammations like lung inflammation in Covid 19.
APA, Harvard, Vancouver, ISO, and other styles
7

Nijen Twilhaar, Maarten K., Lucas Czentner, Joanna Grabowska, Alsya J. Affandi, Chun Yin Jerry Lau, Katarzyna Olesek, Hakan Kalay, et al. "Optimization of Liposomes for Antigen Targeting to Splenic CD169+ Macrophages." Pharmaceutics 12, no. 12 (November 25, 2020): 1138. http://dx.doi.org/10.3390/pharmaceutics12121138.

Full text
Abstract:
Despite promising progress in cancer vaccination, therapeutic effectiveness is often insufficient. Cancer vaccine effectiveness could be enhanced by targeting vaccine antigens to antigen-presenting cells, thereby increasing T-cell activation. CD169-expressing splenic macrophages efficiently capture particulate antigens from the blood and transfer these antigens to dendritic cells for the activation of CD8+ T cells. In this study, we incorporated a physiological ligand for CD169, the ganglioside GM3, into liposomes to enhance liposome uptake by CD169+ macrophages. We assessed how variation in the amount of GM3, surface-attached PEG and liposomal size affected the binding to, and uptake by, CD169+ macrophages in vitro and in vivo. As a proof of concept, we prepared GM3-targeted liposomes containing a long synthetic ovalbumin peptide and tested the capacity of these liposomes to induce CD8+ and CD4+ T-cell responses compared to control liposomes or soluble peptide. The data indicate that the delivery of liposomes to splenic CD169+ macrophages can be optimized by the selection of liposomal constituents and liposomal size. Moreover, optimized GM3-mediated liposomal targeting to CD169+ macrophages induces potent immune responses and therefore presents as an interesting delivery strategy for cancer vaccination.
APA, Harvard, Vancouver, ISO, and other styles
8

Naik, Himgauri, Jafrin Jobayer Sonju, Sitanshu Singh, Ioulia Chatzistamou, Leeza Shrestha, Ted Gauthier, and Seetharama Jois. "Lipidated Peptidomimetic Ligand-Functionalized HER2 Targeted Liposome as Nano-Carrier Designed for Doxorubicin Delivery in Cancer Therapy." Pharmaceuticals 14, no. 3 (March 6, 2021): 221. http://dx.doi.org/10.3390/ph14030221.

Full text
Abstract:
The therapeutic index of chemotherapeutic agents can be improved by the use of nano-carrier-mediated chemotherapeutic delivery. Ligand-targeted drug delivery can be used to achieve selective and specific delivery of chemotherapeutic agents to cancer cells. In this study, we prepared a peptidomimetic conjugate (SA-5)-tagged doxorubicin (Dox) incorporated liposome (LP) formulation (SA-5-Dox-LP) to evaluate the targeted delivery potential of SA-5 in human epidermal growth factor receptor-2 (HER2) overexpressed non-small-cell lung cancer (NSCLC) and breast cancer cell lines. The liposome was prepared using thin lipid film hydration and was characterized for particle size, encapsulation efficiency, cell viability, and targeted cellular uptake. In vivo evaluation of the liposomal formulation was performed in a mice model of NSCLC. The cell viability studies revealed that targeted SA-5-Dox-LP showed better antiproliferative activity than non-targeted Dox liposomes (Dox-LP). HER2-targeted liposome delivery showed selective cellular uptake compared to non-targeted liposomes on cancer cells. In vitro drug release studies indicated that Dox was released slowly from the formulations over 24 h, and there was no difference in Dox release between Dox-LP formulation and SA-5-Dox-LP formulation. In vivo studies in an NSCLC model of mice indicated that SA-5-Dox-LP could reduce the lung tumors significantly compared to vehicle control and Dox. In conclusion, this study demonstrated that the SA-5-Dox-LP liposome has the potential to increase therapeutic efficiency and targeted delivery of Dox in HER2 overexpressing cancer.
APA, Harvard, Vancouver, ISO, and other styles
9

Harokopakis, Evlambia, George Hajishengallis, and Suzanne M. Michalek. "Effectiveness of Liposomes Possessing Surface-Linked Recombinant B Subunit of Cholera Toxin as an Oral Antigen Delivery System." Infection and Immunity 66, no. 9 (September 1, 1998): 4299–304. http://dx.doi.org/10.1128/iai.66.9.4299-4304.1998.

Full text
Abstract:
ABSTRACT Liposomes appear to be a promising oral antigen delivery system for the development of vaccines against infectious diseases, although their uptake efficiency by Peyer’s patches in the gut and the subsequent induction of mucosal immunoglobulin A (IgA) responses remain a major concern. Aiming at targeted delivery of liposomal immunogens, we have previously reported the conjugation via a thioether bond of the GM1 ganglioside-binding subunit of cholera toxin (CTB) to the liposomal outer surface. In the present study, we have investigated the effectiveness of liposomes containing the saliva-binding region (SBR) of Streptococcus mutans AgI/II adhesin and possessing surface-linked recombinant CTB (rCTB) in generating mucosal (salivary, vaginal, and intestinal) IgA as well as serum IgG responses to the parent molecule, AgI/II. Responses in mice given a single oral dose of the rCTB-conjugated liposomes were compared to those in mice given one of the following unconjugated liposome preparations: (i) empty liposomes, (ii) liposomes containing SBR, (iii) liposomes containing SBR and coadministered with rCTB, and (iv) liposomes containing SBR plus rCTB. Three weeks after the primary immunization, significantly higher levels of mucosal IgA and serum IgG antibodies to AgI/II were observed in the rCTB-conjugated group than in mice given the unconjugated liposome preparations, although the latter mice received a booster dose at week 9. The antibody responses in mice immunized with rCTB-conjugated liposomes persisted at high levels for at least 6 months, at which time (week 26) a recall immunization significantly augmented the responses. In general, mice given unconjugated liposome preparations required one or two booster immunizations to develop a substantial anti-AgI/II antibody response, which was more prominent in the group given coencapsulated SBR and rCTB. These data indicate that conjugation of rCTB to liposomes greatly enhances their effectiveness as an antigen delivery system. This oral immunization strategy should be applicable for the development of vaccines against oral, intestinal, or sexually transmitted diseases.
APA, Harvard, Vancouver, ISO, and other styles
10

Nosova, A. S., O. O. Koloskova, I. P. Shilovskiy, Yu L. Sebyakin, and M. R. Khaitov. "Lactose-based glycoconjugates with variable spacers for design of liver-targeted liposomes." Biomeditsinskaya Khimiya 63, no. 5 (2017): 467–71. http://dx.doi.org/10.18097/pbmc20176305467.

Full text
Abstract:
Asialoglycoprotein receptors are highly abundant on the hepatocyte surface and have specific binding sites for blood serum glycoproteins. Such discovery resulted in development of liver-targeted drug delivery systems because modification of the liposomal surface by carbohydrate derivatives results in an increase of endocytosis, which facilitates selective uptake of such systems by hepatocytes. In this study we have synthesized novel lactose derivatives containing a palmitic hydrophobic domain. They were used for modification of the liposome surface. Transfection activity of modified liposomes was analyzed on the HepG2 cell line (hepatocytes) and showed an increase in the transfection efficiency as compared to the non-modified liposomes. At the same time transfection activities of modified and non-modified liposomes were similar in the case of a non-hepatocyte cell line (293T). The novel lactose-based glycoconjugates may be a promising tool for developing efficient vectors for delivery of nucleic acids to hepatocytes.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Targetted liposome"

1

Baki, Mert. "Bone Marrow Targeted Liposomal Drug Delivery Systems." Master's thesis, METU, 2011. http://etd.lib.metu.edu.tr/upload/12613251/index.pdf.

Full text
Abstract:
Homing is the process that stem cells move to their own stem cell niches under the influence of chemokines like stromal-derived factor-1&alpha
(SDF-1&alpha
) upon bone marrow transplantation (BMT). There is a need for increasing homing efficiency after BMT since only 10-15% of the transplanted cells can home to their own niches and a limited amount of donor marrow can be transplanted. In this study, we aimed to develop and characterize bone marrow targeted liposomal SDF-1&alpha
delivery system prepared by extrusion method. Alendronate conjugation was chosen to target the liposomes to bone marrow microenvironment, particularly the endosteal niche. Optimization studies were conducted with the model protein (
APA, Harvard, Vancouver, ISO, and other styles
2

Loughrey, Helen. "Targeted liposomes." Thesis, University of British Columbia, 1989. http://hdl.handle.net/2429/29180.

Full text
Abstract:
This thesis presents an optimized and general procedure for coupling proteins to liposomes and investigates certain aspects of the interaction of liposomes with components of the circulation. The object of these studies was to develop straightforward methods for the preparation of well characterized protein-liposome conjugates which exhibit extended circulation half-lives in the blood. These favorable properties should potentiate the use of protein coupled vesicles in in vivo applications such as targeting or diagnostic protocols. A general approach for the preparation of protein-liposome conjugates was developed which employs the high affinity binding of streptavidin for biotinated proteins. Streptavidin was initially attached in a non-covalent manner (via biotin phosphatidylethanolamine) or covalently (via maleimidophenyl-butyryl phosphatidyl-ethanolamine, MPB-PE or pyridyldithio-propionyl phosphatidylethanolamine, PDP-PE) to pre-formed liposomes containing the various lipid derivatives. It was shown that the procedure based on the maleimide derivative MPB-PE, was the most efficient coupling method. Standard procedures for the preparation of MPB-PE however, were found to result in an impure product. Recently a new method for the synthesis of a pure SMPB derivative of phosphatidylethanolamine was developed (Lewis Choi, unpublished). Efficient coupling of proteins to liposomes containing low amounts of pure MPB-DPPE was achieved. Subsequently it was shown that gentle incubation with biotinated proteins results in the rapid and efficient generation of protein coupled vesicles. These retain their ability to interact with defined target celte. Aggregation of liposomes during the coupling reaction is a common consequence of the efficient coupling of protein to liposomes. A method was therefore developed for the preparation of small homogeneously sized protein-liposome conjugates by an extrusion process which does not denature the attached protein. These extruded samples exhibited extended blood circulation times and were stable for significant periods in vivo. The second part of this thesis investigated the in vitro interaction of liposomes of various lipid compositions with platelets. It was demonstrated that large liposomes (> 200 nm in diameter) containing negatively charged lipids (such as EPG) or thiol reactive lipid derivatives (such as MPB-PE) can induce aggregation of platelets in vitro. This interaction was mediated by complement. It is suggested that the formation of platelet-liposome microaggregates in vivo on intravenous administration of negatively charged liposomes, resulted in the transient thrombocytopenia observed in rats. This adhesion event may have also contributed to the rapid removal of aggregated protein-liposome conjugates (containing MPB-PE) from the circulation.
Medicine, Faculty of
Biochemistry and Molecular Biology, Department of
Graduate
APA, Harvard, Vancouver, ISO, and other styles
3

Harasym, Troy O. "Antibody-targeted liposomal systems." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1997. http://www.collectionscanada.ca/obj/s4/f2/dsk3/ftp04/nq25066.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Bowen, Tian. "Liposome-QD hybrids and the development of targeted theranostic modalities." Thesis, University of London, 2010. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.535499.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Javadi, Marjan. "Novel Liposomes for Targeted Delivery of Drugs and Plasmids." BYU ScholarsArchive, 2013. https://scholarsarchive.byu.edu/etd/3879.

Full text
Abstract:
People receiving chemotherapy not only suffer from side effects of therapeutics but also must buy expensive drugs. Targeted drug and gene delivery directed to specific tumor-cells is one way to reduce the side effect of drugs and use less amount of therapeutics. In this research, two novel liposomal nanocarriers were developed. This nanocarrier, called an eLiposome, is basically one or more emulsion droplets inside a liposome. Emulsion droplets are made of perfluorocarbons which usually have a high vapor pressure. Calcein (as a model drug) and Paclitaxel were used to demonstrate drug delivery, and plasmids and siRNA were used to exemplify gene delivery. Drugs or genes were encapsulated inside the interior of the liposomes along with emulsion droplets; targeting moieties were attached to the outside of the phospholipid bilayer. Ultrasound was used to break open the bilayer by changing the liquid emulsion droplets to gas, which released the content of the eLiposomes. Transmission electron microscopy (TEM) was used to prove the formation of eLiposomes and confocal microscopy showed the uptake of drugs and genes in vitro. Cell viability was measured to show the effect of uptake in cancer cells. Results indicate that eLiposomes were successfully made and that they were endocytosed into the cell. It was observed that the emulsion and the targeting moiety in combination with ultrasound are the essential elements required to produce release from eLiposomes.
APA, Harvard, Vancouver, ISO, and other styles
6

Harrington, Kevin Joseph. "Pegylated Liposome-targeted Radiosensitisers for the Treatment of Head and neck Cancer." Thesis, Imperial College London, 2009. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.506160.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Divi, Murali Krishna. "Development and evaluation of brain tumor targeted liposome delivery system for paclitaxel." View the abstract Download the full-text PDF version, 2008. http://etd.utmem.edu/ABSTRACTS/2007-012-Divi-index.html.

Full text
Abstract:
Thesis (Ph.D.)--University of Tennessee Health Science Center, 2008.
Title from title page screen (viewed on January 6, 2009). Research advisor: George C Wood, Ph.D. Document formatted into pages (xii, 126 p. : ill.). Vita. Abstract. Includes bibliographical references (p. 112-126).
APA, Harvard, Vancouver, ISO, and other styles
8

Stevens, Phillip James. "An approach to drug formulation and targeting liposomes and lipid nanoparticles for folate receptor targeting." Connect to this title online, 2005. http://rave.ohiolink.edu/etdc/view?acc%5Fnum=osu1111092653.

Full text
Abstract:
Thesis (Ph. D.)--Ohio State University, 2005.
Title from first page of PDF file. Document formatted into pages; contains xvi, 110 p.; also includes graphics (some col.) Includes bibliographical references (p. 98-110). Available online via OhioLINK's ETD Center
APA, Harvard, Vancouver, ISO, and other styles
9

Hartley, Jonathan Michael. "Surface Modification of Liposomes Containing Nanoemulsions." BYU ScholarsArchive, 2011. https://scholarsarchive.byu.edu/etd/2846.

Full text
Abstract:
Many attempts have been made to make cancer therapy more selective and less detrimental to the health of the patients. Nanoparticles have emerged as a way to solve some of the problems of traditional chemotherapy. Nanoparticles can provide protection for the therapeutic from degradation or clearance, as well as protection to healthy tissue from the damaging effects of chemotherapy drugs. Researchers are pursuing different strategies but all have the same goals of improving the outcomes of cancer patients. The field of controlled release of drugs has increased significantly in hopes of better treating diseases like cancer. Improved control of drug release has great potential for improving patient outcomes. Still there exist certain barriers such as circulation time, cell specificity, and endosomal escape.In this study a novel drug delivery vehicle was studied in vitro. The novel construct consisted of a liposome containing perfluorocarbon emulsions—an eLiposome—that was activated by ultrasound to break open on demand. Two targeting moieties were attached to the eLiposome to increase cell specificity and induce endocytosis. These studies determined the localization of eLiposomes in vitro using flow cytometry and confocal microscopy. Results indicated that eLiposomes modified with a targeting moiety attached to HeLa cells to a greater extent than non-targeting eLiposomes. Confocal images indicated localization of eLiposomes around the membrane of cells. Flow cytometer results indicated that ultrasound does in fact disrupt the eLiposomes but evidence of significant delivery to the cytoplasm was not obtained. However cells that were incubated with eLiposomes for 24 hours showed over 60% of the cells had green color association indicating eLiposome uptake.
APA, Harvard, Vancouver, ISO, and other styles
10

Jayanna, Prashanth K. Petrenko Valery. "Therapeutic liposomes for prostate cancer targeted by phage fusion coat proteins." Auburn, Ala., 2009. http://hdl.handle.net/10415/1994.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Targetted liposome"

1

1960-, Tyle Praveen, and Ram Bhanu P. 1951-, eds. Targeted therapeutic systems. New York: Dekker, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Bicanic, Tihana, and Thomas S. Harrison. Fungal central nervous system infections. Edited by Christopher C. Kibbler, Richard Barton, Neil A. R. Gow, Susan Howell, Donna M. MacCallum, and Rohini J. Manuel. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198755388.003.0022.

Full text
Abstract:
Infections of the central nervous system (CNS) are amongst the most severe of all fungal infections. Cryptococcus neoformans is the commonest cause of adult meningitis in many countries with high HIV prevalence. C gattii is usually seen in the tropics in apparently immunocompetent patients. Meningitis is also caused by Candida in premature babies, and by the dimorphic fungi in endemic areas. CNS infections with Aspergillus, the mucormycetes, and less common moulds usually present as intracranial mass lesions in immunocompromised hosts. Early suspicion, prompt imaging, and appropriate samples for culture, histology, and antigen and molecular tests are all critical for early diagnosis. Organism-specific antifungal therapy relies largely on liposomal amphotericin B and voriconazole, with therapeutic drug monitoring for the latter. Amphotericin B plus flucytosine is recommended for cryptococcal meningitis. Management of underlying conditions is also critical. Targeted prophylaxis in highest risk groups and pre-emptive therapy for HIV-associated cryptococcosis hold promise for prevention and improved outcome.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Targetted liposome"

1

Vyas, Suresh Prasad, Amit K. Goyal, and Kapil Khatri. "Mannosylated Liposomes for Targeted Vaccines Delivery." In Methods in Molecular Biology, 177–88. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60327-360-2_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Pradhan, Pallab, Rinti Banerjee, Dhirendra Bahadur, Christian Koch, Olga Mykhaylyk, and Christian Plank. "Targeted Magnetic Liposomes Loaded with Doxorubicin." In Methods in Molecular Biology, 279–93. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60327-360-2_19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Pradhan, Pallab, Rinti Banerjee, Dhirendra Bahadur, Christian Koch, Olga Mykhaylyk, and Christian Plank. "Targeted Magnetic Liposomes Loaded with Doxorubicin." In Methods in Molecular Biology, 257–72. New York, NY: Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4939-6591-5_21.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Lai, Francesco, Michele Schlich, Chiara Sinico, and Anna Maria Fadda. "Liposomes as Brain Targeted Delivery Systems." In Neuromethods, 29–59. New York, NY: Springer US, 2020. http://dx.doi.org/10.1007/978-1-0716-0838-8_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

He, W. "Chapter 20. Liposomes in Targeted Drug Delivery." In Soft Matter Series, 499–517. Cambridge: Royal Society of Chemistry, 2021. http://dx.doi.org/10.1039/9781839161124-00499.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Scherphof, G. L. "In Vivo Behavior of Liposomes: Interactions with the Mononuclear Phagocyte System and Implications for Drug Targeting." In Targeted Drug Delivery, 285–327. Berlin, Heidelberg: Springer Berlin Heidelberg, 1991. http://dx.doi.org/10.1007/978-3-642-75862-1_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Milani, Doniya, Umi Athiyah, Dewi Melani Hariyadi, and Yashwant V. Pathak. "Surface Modifications of Liposomes for Drug Targeting." In Surface Modification of Nanoparticles for Targeted Drug Delivery, 207–20. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-06115-9_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Gabizon, Alberto, Hilary Shmeeda, Hemda Baabur-Cohen, and Ronit Satchi-Fainaro. "Liposomes and Polymers in Folate-Targeted Cancer Therapeutics." In Targeted Drug Strategies for Cancer and Inflammation, 217–47. Boston, MA: Springer US, 2011. http://dx.doi.org/10.1007/978-1-4419-8417-3_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Guliani, Anika, Rubbel Singla, Avnesh Kumari, and Sudesh Kumar Yadav. "Liposomal and Phytosomal Formulations." In Nanoscale Materials in Targeted Drug Delivery, Theragnosis and Tissue Regeneration, 81–102. Singapore: Springer Singapore, 2016. http://dx.doi.org/10.1007/978-981-10-0818-4_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Erdogan, Suna, and Vladimir P. Torchilin. "Gadolinium-Loaded Polychelating Polymer-Containing Tumor-Targeted Liposomes." In Methods in Molecular Biology, 179–92. New York, NY: Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4939-6591-5_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Targetted liposome"

1

Zhang, Aili, Xipeng Mi, and Lisa X. Xu. "Study of Thermally Targeted Nano-Particle Drug Delivery for Tumor Therapy." In ASME 2008 First International Conference on Micro/Nanoscale Heat Transfer. ASMEDC, 2008. http://dx.doi.org/10.1115/mnht2008-52383.

Full text
Abstract:
The efficacy of cancer chemotherapeutics could be greatly enhanced by thermally targeted nanoparticle liposome drug delivery system. The tumor microvasculature response to hyperthermia and its permeability to the nano-liposomes were studied using the 4T1 mouse model and confocal fluorescence microscopy. Based on the experimental results, a new theoretical model was developed to describe the distributions of both the liposomal and free drug released as liposomes broke in tumor for treatment evaluation. In this model, the tumor was divided into two regions: peripheral and central. The drug effect on the tumor cell apoptosis and necrosis was considered. Upon the experimental validation, the model was used to simulate drug distribution in the tumor under either the hyperthermic or the alternate freezing and heating condition. Results showed that hyperthermia alone only enhanced drug accumulation in the tumor periphery and therefore more serious tumor damage induced in the region. But the tumor cells in the central region were hardly damaged due to the lack of drug diffusion. The alternate freezing and heating was proposed to aid the nanoliposomal drug delivery, and better results were found.
APA, Harvard, Vancouver, ISO, and other styles
2

Tartis, Michaelann S., Jan Marik, Azadeh Kheirolomoom, Rachel E. Pollard, Hua Zhang, Jinyi Qi, Julie L. Sutcliffe, and Katherine W. Ferrara. "Pharmacokinetics of Encapsulated Paclitaxel: Multi-Probe Analysis With PET." In ASME 2007 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2007. http://dx.doi.org/10.1115/sbc2007-176435.

Full text
Abstract:
We have combined two imaging probes and used PET as a means to provide image-based validation for a novel targeted drug delivery system. The first probe was a direct labeling of the drug [18F]fluoropaclitaxel [1–3], which was inserted into various carrier vehicle formulations. The second probe, [18F]fluoro-1,2-dipalmitoyl-sn-glycerol, i.e. [18F]FDP involved radiolabeling the lipid vehicle. Paclitaxel, which is poorly soluble in aqueous media, also has limited solubility and stability in lipophilic environments such as liposomes. Stable association of paclitaxel with the lipid bilayer is affected by a variety of physicochemical factors such as temperature and liposome composition. Paclitaxel crystal formation has been documented, with two forms of solid state within aqueous media and organic solvents, although crystal conformation differs in each media [4,5]. We provide dynamic in vivo image sets providing biodistribution and time activity curves of free [18F]fluoropaclitaxel and liposomal [18F]fluoropaclitaxel as well as free [18F]FDP, liposomal [18F]FDP, and [18F]FDP in an ultrasound contrast agent. Serial studies were performed within a small group of rats, minimizing inter-animal variability. The two labeled molecules have different biodistributions: paclitaxel is rapidly taken up in the liver, intestines and kidneys, while the labeled lipid incorporated into liposomes stays in circulation with minimal uptake in organs other than spleen. Here, we have developed a quantitative method to follow paclitaxel and lipid vehicles to their destination in vivo in order to improve targeted paclitaxel delivery.
APA, Harvard, Vancouver, ISO, and other styles
3

Mulamalla, Hari Chandana R., Maria P. Lambros, and Ying Huang. "Abstract 5514: Targeted liposomes in cancer therapy." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-5514.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Espelin, C., E. Geretti, S. Coma, Z. Koncki, S. Leonard, N. Dumont, J. Reynolds, I. Molnar, and T. Wickham. "Abstract P3-06-05: Receptor-mediated binding of HER2-targeted antibody-liposomal doxorubicin conjugate MM-302 increases liposome binding, nuclear doxorubicin, DNA damage and efficacy relative to untargeted PEGylated liposomal doxorubicin (PLD/Doxil)." In Abstracts: 2016 San Antonio Breast Cancer Symposium; December 6-10, 2016; San Antonio, Texas. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.sabcs16-p3-06-05.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Matviykiv, Sofiya, Marzia Buscema, Tamás Mészáros, Gabriela Gerganova, Thomas Pfohl, Andreas Zumbühl, János Szebeni, and Bert Müller. "Liposomes: bio-inspired nano-containers for physically triggered targeted drug delivery." In SPIE Smart Structures and Materials + Nondestructive Evaluation and Health Monitoring, edited by Mato Knez, Akhlesh Lakhtakia, and Raúl J. Martín-Palma. SPIE, 2017. http://dx.doi.org/10.1117/12.2258378.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Yokoyama, Tomohisa, Yoichi Osato, Keisuke Miyazawa, Akime Miyasato, Hiroko Hayabe, Masaharu Nomura, Noriko Gotoh, et al. "Abstract 2904: EGFR-targeted gold liposome for molecular imaging and therapy on NSCLC cells." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-2904.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Mriouah, Jihane M., Rae Lynn Nesbitt, Deborah Sosnowski, Desmond Pink, Roy Duncan, Andries Ziljstra, and John D. Lewis. "Abstract 2192: Fusogenic targeted liposomes as next-generation nanomedicine for prostate cancer." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-2192.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Nesbitt, Rae, Desmond Pink, Roy Duncan, and John Lewis. "Abstract 3224: Targeted non-invasive therapy of prostate cancer using fusogenic liposomes." In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-3224.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Omata, Daiki, Yoichi Negishi, Yoko Endo-Takahashi, Ryo Suzuki, Kazuo Maruyama, Motoyoshi Nomizu, Yukihiko Aramaki, Yoichiro Matsumoto, Lawrence A. Crum, and Gail Reinette ter Haar. "Ultrasound-targeted Bubble Liposome Destruction Enhances AG73-mediated Gene Transfer by Improvement of Intracellular Trafficking." In 10TH INTERNATIONAL SYMPOSIUM ON THERAPEUTIC ULTRASOUND (ISTU 2010). AIP, 2011. http://dx.doi.org/10.1063/1.3607927.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Xia, Zongxin, Hong Yang, Fei Li, Shulai Zhu, and Ying Xing. "The research of targeted liposome embedding brain-derived neurotrophic factor through the blood–brain barrier." In International Conference on Modern Engineering Soultions for the Industry. Southampton, UK: WIT Press, 2014. http://dx.doi.org/10.2495/mesi140972.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Targetted liposome"

1

Onyuksel, Hayat. Tc-99m Labeled and VIP Receptor Targeted Liposomes for Effective Imaging of Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, September 2004. http://dx.doi.org/10.21236/ada433960.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Targetted liposome' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography